nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—rheumatoid arthritis—systemic scleroderma	0.71	1	CtDrD
Auranofin—ALB—Captopril—systemic scleroderma	0.0547	0.366	CbGbCtD
Auranofin—ALB—Mycophenolate mofetil—systemic scleroderma	0.0431	0.288	CbGbCtD
Auranofin—ALB—Prednisone—systemic scleroderma	0.0344	0.23	CbGbCtD
Auranofin—ALB—Methotrexate—systemic scleroderma	0.0173	0.116	CbGbCtD
Auranofin—PRDX5—connective tissue—systemic scleroderma	0.00269	0.148	CbGeAlD
Auranofin—PRDX5—skin of body—systemic scleroderma	0.00243	0.133	CbGeAlD
Auranofin—PRDX5—digestive system—systemic scleroderma	0.00195	0.107	CbGeAlD
Auranofin—PRDX5—tendon—systemic scleroderma	0.00185	0.101	CbGeAlD
Auranofin—PRDX5—lung—systemic scleroderma	0.00163	0.089	CbGeAlD
Auranofin—IKBKB—connective tissue—systemic scleroderma	0.0016	0.0874	CbGeAlD
Auranofin—IKBKB—smooth muscle tissue—systemic scleroderma	0.00146	0.0799	CbGeAlD
Auranofin—IKBKB—skin of body—systemic scleroderma	0.00144	0.0789	CbGeAlD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TNIP1—systemic scleroderma	0.00136	0.0425	CbGpPWpGaD
Auranofin—PRDX5—Selenium Micronutrient Network—CCL2—systemic scleroderma	0.00122	0.038	CbGpPWpGaD
Auranofin—IKBKB—digestive system—systemic scleroderma	0.00115	0.0631	CbGeAlD
Auranofin—IKBKB—tendon—systemic scleroderma	0.0011	0.0601	CbGeAlD
Auranofin—IKBKB—Canonical NF-kappaB pathway—TNFAIP3—systemic scleroderma	0.00104	0.0326	CbGpPWpGaD
Auranofin—IKBKB—lung—systemic scleroderma	0.000962	0.0527	CbGeAlD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—GDF15—systemic scleroderma	0.000953	0.0298	CbGpPWpGaD
Auranofin—PRDX5—Selenium Micronutrient Network—IL1B—systemic scleroderma	0.000923	0.0288	CbGpPWpGaD
Auranofin—IKBKB—NOD1/2 Signaling Pathway—TNFAIP3—systemic scleroderma	0.000822	0.0257	CbGpPWpGaD
Auranofin—IKBKB—GMCSF-mediated signaling events—IRF8—systemic scleroderma	0.000762	0.0238	CbGpPWpGaD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—systemic scleroderma	0.000747	0.0233	CbGpPWpGaD
Auranofin—PRDX5—Cellular responses to stress—IL1A—systemic scleroderma	0.000735	0.0229	CbGpPWpGaD
Auranofin—IKBKB—Downstream TCR signaling—CD247—systemic scleroderma	0.000702	0.0219	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling in naïve CD8+ T cells—CSK—systemic scleroderma	0.000608	0.019	CbGpPWpGaD
Auranofin—IKBKB—TNF receptor signaling pathway —TNFAIP3—systemic scleroderma	0.000599	0.0187	CbGpPWpGaD
Auranofin—IKBKB—Hair Follicle Development: Induction (Part 1 of 3)—CTGF—systemic scleroderma	0.000574	0.0179	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling in naïve CD8+ T cells—CD247—systemic scleroderma	0.000571	0.0178	CbGpPWpGaD
Auranofin—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—systemic scleroderma	0.000561	0.0175	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling—CSK—systemic scleroderma	0.000558	0.0174	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—RHOB—systemic scleroderma	0.00054	0.0169	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling—CD247—systemic scleroderma	0.000524	0.0164	CbGpPWpGaD
Auranofin—ALB—Lipoprotein metabolism—HSPG2—systemic scleroderma	0.000524	0.0164	CbGpPWpGaD
Auranofin—IKBKB—Osteopontin Signaling—MMP9—systemic scleroderma	0.000513	0.016	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling in naïve CD4+ T cells—CSK—systemic scleroderma	0.00051	0.0159	CbGpPWpGaD
Auranofin—IKBKB—BCR signaling pathway—CSK—systemic scleroderma	0.000504	0.0157	CbGpPWpGaD
Auranofin—Hepatic enzyme increased—Mycophenolate mofetil—systemic scleroderma	0.000502	0.00559	CcSEcCtD
Auranofin—IKBKB—IL1-mediated signaling events—IL1A—systemic scleroderma	0.000483	0.0151	CbGpPWpGaD
Auranofin—IKBKB—TCR signaling in naïve CD4+ T cells—CD247—systemic scleroderma	0.000479	0.015	CbGpPWpGaD
Auranofin—Eosinophilia—Captopril—systemic scleroderma	0.000475	0.00529	CcSEcCtD
Auranofin—Conjunctivitis—Mometasone—systemic scleroderma	0.000474	0.00527	CcSEcCtD
Auranofin—Melaena—Mycophenolate mofetil—systemic scleroderma	0.000464	0.00516	CcSEcCtD
Auranofin—Pancytopenia—Captopril—systemic scleroderma	0.000456	0.00508	CcSEcCtD
Auranofin—Neutropenia—Captopril—systemic scleroderma	0.000449	0.005	CcSEcCtD
Auranofin—Aplastic anaemia—Mycophenolate mofetil—systemic scleroderma	0.000446	0.00496	CcSEcCtD
Auranofin—IKBKB—Downstream TCR signaling—HLA-DQB1—systemic scleroderma	0.000438	0.0137	CbGpPWpGaD
Auranofin—Gastrointestinal haemorrhage—Mycophenolic acid—systemic scleroderma	0.000437	0.00486	CcSEcCtD
Auranofin—Flatulence—Pentoxifylline—systemic scleroderma	0.000435	0.00484	CcSEcCtD
Auranofin—Weight decreased—Captopril—systemic scleroderma	0.000434	0.00483	CcSEcCtD
Auranofin—Dysgeusia—Pentoxifylline—systemic scleroderma	0.000432	0.00481	CcSEcCtD
Auranofin—IKBKB—Interleukin-1 signaling—IL1A—systemic scleroderma	0.000424	0.0132	CbGpPWpGaD
Auranofin—Jaundice—Captopril—systemic scleroderma	0.000417	0.00464	CcSEcCtD
Auranofin—Stomatitis—Captopril—systemic scleroderma	0.000417	0.00464	CcSEcCtD
Auranofin—IKBKB—Apoptosis—IRF5—systemic scleroderma	0.000414	0.0129	CbGpPWpGaD
Auranofin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL1A2—systemic scleroderma	0.000408	0.0128	CbGpPWpGaD
Auranofin—Anaemia—Pentoxifylline—systemic scleroderma	0.000408	0.00454	CcSEcCtD
Auranofin—Angioedema—Pentoxifylline—systemic scleroderma	0.000403	0.00449	CcSEcCtD
Auranofin—Agranulocytosis—Captopril—systemic scleroderma	0.0004	0.00445	CcSEcCtD
Auranofin—Pancytopenia—Azathioprine—systemic scleroderma	0.000398	0.00443	CcSEcCtD
Auranofin—Leukopenia—Pentoxifylline—systemic scleroderma	0.000395	0.0044	CcSEcCtD
Auranofin—Eosinophilia—Leflunomide—systemic scleroderma	0.000392	0.00436	CcSEcCtD
Auranofin—IKBKB—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TNFAIP3—systemic scleroderma	0.000385	0.012	CbGpPWpGaD
Auranofin—Interstitial lung disease—Methotrexate—systemic scleroderma	0.00038	0.00423	CcSEcCtD
Auranofin—Dysphagia—Mycophenolic acid—systemic scleroderma	0.000378	0.0042	CcSEcCtD
Auranofin—Pancytopenia—Leflunomide—systemic scleroderma	0.000376	0.00418	CcSEcCtD
Auranofin—IKBKB—TCR Signaling Pathway—CD247—systemic scleroderma	0.000374	0.0117	CbGpPWpGaD
Auranofin—IKBKB—Structural Pathway of Interleukin 1 (IL-1)—IL1A—systemic scleroderma	0.000373	0.0116	CbGpPWpGaD
Auranofin—Neutropenia—Leflunomide—systemic scleroderma	0.00037	0.00412	CcSEcCtD
Auranofin—Pancytopenia—Mycophenolic acid—systemic scleroderma	0.000359	0.00399	CcSEcCtD
Auranofin—Weight decreased—Leflunomide—systemic scleroderma	0.000358	0.00398	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—IRF5—systemic scleroderma	0.000354	0.0111	CbGpPWpGaD
Auranofin—Neutropenia—Mycophenolic acid—systemic scleroderma	0.000353	0.00393	CcSEcCtD
Auranofin—Thrombocytopenia—Pentoxifylline—systemic scleroderma	0.000353	0.00393	CcSEcCtD
Auranofin—Agranulocytosis—Azathioprine—systemic scleroderma	0.000349	0.00388	CcSEcCtD
Auranofin—ALB—Lipid and lipoprotein metabolism—HSPG2—systemic scleroderma	0.000348	0.0109	CbGpPWpGaD
Auranofin—Angioedema—Mometasone—systemic scleroderma	0.000348	0.00387	CcSEcCtD
Auranofin—Neuropathy peripheral—Leflunomide—systemic scleroderma	0.000346	0.00385	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Mycophenolate mofetil—systemic scleroderma	0.000345	0.00384	CcSEcCtD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TNFAIP3—systemic scleroderma	0.000344	0.0107	CbGpPWpGaD
Auranofin—Jaundice—Leflunomide—systemic scleroderma	0.000344	0.00383	CcSEcCtD
Auranofin—Stomatitis—Leflunomide—systemic scleroderma	0.000344	0.00383	CcSEcCtD
Auranofin—Anorexia—Pentoxifylline—systemic scleroderma	0.000343	0.00382	CcSEcCtD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—BLK—systemic scleroderma	0.000343	0.0107	CbGpPWpGaD
Auranofin—Conjunctivitis—Leflunomide—systemic scleroderma	0.000343	0.00382	CcSEcCtD
Auranofin—Gingivitis—Methotrexate—systemic scleroderma	0.000343	0.00381	CcSEcCtD
Auranofin—Weight decreased—Mycophenolic acid—systemic scleroderma	0.000342	0.0038	CcSEcCtD
Auranofin—Alopecia—Captopril—systemic scleroderma	0.00034	0.00378	CcSEcCtD
Auranofin—Eosinophilia—Lisinopril—systemic scleroderma	0.000337	0.00375	CcSEcCtD
Auranofin—Haematuria—Leflunomide—systemic scleroderma	0.000336	0.00374	CcSEcCtD
Auranofin—Neuropathy peripheral—Mycophenolic acid—systemic scleroderma	0.00033	0.00367	CcSEcCtD
Auranofin—Agranulocytosis—Leflunomide—systemic scleroderma	0.000329	0.00366	CcSEcCtD
Auranofin—IKBKB—IL-1 signaling pathway—IL1A—systemic scleroderma	0.000329	0.0103	CbGpPWpGaD
Auranofin—Stomatitis—Mycophenolic acid—systemic scleroderma	0.000328	0.00365	CcSEcCtD
Auranofin—Jaundice—Mycophenolic acid—systemic scleroderma	0.000328	0.00365	CcSEcCtD
Auranofin—Dysgeusia—Captopril—systemic scleroderma	0.000328	0.00365	CcSEcCtD
Auranofin—IKBKB—TCR signaling—HLA-DQB1—systemic scleroderma	0.000327	0.0102	CbGpPWpGaD
Auranofin—Conjunctivitis—Mycophenolic acid—systemic scleroderma	0.000327	0.00364	CcSEcCtD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—BLK—systemic scleroderma	0.000326	0.0102	CbGpPWpGaD
Auranofin—Pancytopenia—Lisinopril—systemic scleroderma	0.000323	0.00359	CcSEcCtD
Auranofin—Haematuria—Mycophenolic acid—systemic scleroderma	0.000321	0.00357	CcSEcCtD
Auranofin—Neutropenia—Lisinopril—systemic scleroderma	0.000318	0.00354	CcSEcCtD
Auranofin—Dyspepsia—Pentoxifylline—systemic scleroderma	0.000317	0.00353	CcSEcCtD
Auranofin—Agranulocytosis—Mycophenolic acid—systemic scleroderma	0.000314	0.0035	CcSEcCtD
Auranofin—Decreased appetite—Pentoxifylline—systemic scleroderma	0.000313	0.00349	CcSEcCtD
Auranofin—IKBKB—GMCSF-mediated signaling events—CCL2—systemic scleroderma	0.00031	0.0097	CbGpPWpGaD
Auranofin—Anaemia—Captopril—systemic scleroderma	0.000309	0.00344	CcSEcCtD
Auranofin—Constipation—Pentoxifylline—systemic scleroderma	0.000308	0.00343	CcSEcCtD
Auranofin—Weight decreased—Lisinopril—systemic scleroderma	0.000308	0.00342	CcSEcCtD
Auranofin—Proteinuria—Methotrexate—systemic scleroderma	0.000306	0.00341	CcSEcCtD
Auranofin—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000306	0.00955	CbGpPWpGaD
Auranofin—Angioedema—Captopril—systemic scleroderma	0.000306	0.0034	CcSEcCtD
Auranofin—Protein urine present—Methotrexate—systemic scleroderma	0.000302	0.00336	CcSEcCtD
Auranofin—Dysphagia—Mycophenolate mofetil—systemic scleroderma	0.000298	0.00332	CcSEcCtD
Auranofin—Neuropathy peripheral—Lisinopril—systemic scleroderma	0.000297	0.00331	CcSEcCtD
Auranofin—Alopecia—Azathioprine—systemic scleroderma	0.000296	0.0033	CcSEcCtD
Auranofin—Anorexia—Mometasone—systemic scleroderma	0.000296	0.0033	CcSEcCtD
Auranofin—Eye disorder—Leflunomide—systemic scleroderma	0.000296	0.00329	CcSEcCtD
Auranofin—Jaundice—Lisinopril—systemic scleroderma	0.000296	0.00329	CcSEcCtD
Auranofin—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.000295	0.00328	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000293	0.00916	CbGpPWpGaD
Auranofin—Glossitis—Methotrexate—systemic scleroderma	0.000292	0.00325	CcSEcCtD
Auranofin—Visual impairment—Mycophenolic acid—systemic scleroderma	0.000291	0.00324	CcSEcCtD
Auranofin—Haematuria—Lisinopril—systemic scleroderma	0.000289	0.00322	CcSEcCtD
Auranofin—Urticaria—Pentoxifylline—systemic scleroderma	0.000286	0.00319	CcSEcCtD
Auranofin—Abdominal pain—Pentoxifylline—systemic scleroderma	0.000285	0.00317	CcSEcCtD
Auranofin—Hepatic enzyme increased—Methotrexate—systemic scleroderma	0.000284	0.00317	CcSEcCtD
Auranofin—Pancytopenia—Mycophenolate mofetil—systemic scleroderma	0.000283	0.00315	CcSEcCtD
Auranofin—Agranulocytosis—Lisinopril—systemic scleroderma	0.000283	0.00315	CcSEcCtD
Auranofin—Eye disorder—Mycophenolic acid—systemic scleroderma	0.000282	0.00314	CcSEcCtD
Auranofin—IKBKB—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.000281	0.00876	CbGpPWpGaD
Auranofin—Alopecia—Leflunomide—systemic scleroderma	0.00028	0.00312	CcSEcCtD
Auranofin—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.000279	0.0031	CcSEcCtD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000276	0.00863	CbGpPWpGaD
Auranofin—Dyspepsia—Mometasone—systemic scleroderma	0.000274	0.00305	CcSEcCtD
Auranofin—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000272	0.00849	CbGpPWpGaD
Auranofin—Flatulence—Leflunomide—systemic scleroderma	0.000272	0.00302	CcSEcCtD
Auranofin—Decreased appetite—Mometasone—systemic scleroderma	0.00027	0.00301	CcSEcCtD
Auranofin—Dysgeusia—Leflunomide—systemic scleroderma	0.00027	0.00301	CcSEcCtD
Auranofin—Anaemia—Azathioprine—systemic scleroderma	0.00027	0.003	CcSEcCtD
Auranofin—Weight decreased—Mycophenolate mofetil—systemic scleroderma	0.00027	0.003	CcSEcCtD
Auranofin—Thrombocytopenia—Captopril—systemic scleroderma	0.000267	0.00298	CcSEcCtD
Auranofin—Alopecia—Mycophenolic acid—systemic scleroderma	0.000267	0.00297	CcSEcCtD
Auranofin—Melaena—Methotrexate—systemic scleroderma	0.000263	0.00292	CcSEcCtD
Auranofin—Leukopenia—Azathioprine—systemic scleroderma	0.000261	0.00291	CcSEcCtD
Auranofin—IKBKB—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000261	0.00816	CbGpPWpGaD
Auranofin—Neuropathy peripheral—Mycophenolate mofetil—systemic scleroderma	0.00026	0.0029	CcSEcCtD
Auranofin—Anorexia—Captopril—systemic scleroderma	0.00026	0.0029	CcSEcCtD
Auranofin—Flatulence—Mycophenolic acid—systemic scleroderma	0.000259	0.00288	CcSEcCtD
Auranofin—Stomatitis—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00288	CcSEcCtD
Auranofin—Jaundice—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00288	CcSEcCtD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000259	0.00808	CbGpPWpGaD
Auranofin—Conjunctivitis—Mycophenolate mofetil—systemic scleroderma	0.000258	0.00287	CcSEcCtD
Auranofin—Pruritus—Pentoxifylline—systemic scleroderma	0.000255	0.00284	CcSEcCtD
Auranofin—Anaemia—Leflunomide—systemic scleroderma	0.000255	0.00284	CcSEcCtD
Auranofin—Gastrointestinal pain—Mometasone—systemic scleroderma	0.000254	0.00283	CcSEcCtD
Auranofin—Haematuria—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00282	CcSEcCtD
Auranofin—Aplastic anaemia—Methotrexate—systemic scleroderma	0.000253	0.00281	CcSEcCtD
Auranofin—Angioedema—Leflunomide—systemic scleroderma	0.000252	0.0028	CcSEcCtD
Auranofin—IKBKB—IL1-mediated signaling events—IL1B—systemic scleroderma	0.000252	0.00787	CbGpPWpGaD
Auranofin—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.000248	0.00276	CcSEcCtD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000247	0.00773	CbGpPWpGaD
Auranofin—Leukopenia—Leflunomide—systemic scleroderma	0.000247	0.00275	CcSEcCtD
Auranofin—Diarrhoea—Pentoxifylline—systemic scleroderma	0.000247	0.00274	CcSEcCtD
Auranofin—Abdominal pain—Mometasone—systemic scleroderma	0.000246	0.00274	CcSEcCtD
Auranofin—Anaemia—Mycophenolic acid—systemic scleroderma	0.000243	0.00271	CcSEcCtD
Auranofin—Alopecia—Lisinopril—systemic scleroderma	0.000241	0.00268	CcSEcCtD
Auranofin—Dyspepsia—Captopril—systemic scleroderma	0.00024	0.00268	CcSEcCtD
Auranofin—Decreased appetite—Captopril—systemic scleroderma	0.000237	0.00264	CcSEcCtD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000236	0.00736	CbGpPWpGaD
Auranofin—Leukopenia—Mycophenolic acid—systemic scleroderma	0.000235	0.00262	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Prednisone—systemic scleroderma	0.000234	0.0026	CcSEcCtD
Auranofin—Constipation—Captopril—systemic scleroderma	0.000234	0.0026	CcSEcCtD
Auranofin—Flatulence—Lisinopril—systemic scleroderma	0.000233	0.0026	CcSEcCtD
Auranofin—Thrombocytopenia—Azathioprine—systemic scleroderma	0.000233	0.0026	CcSEcCtD
Auranofin—Dysgeusia—Lisinopril—systemic scleroderma	0.000232	0.00258	CcSEcCtD
Auranofin—Visual impairment—Mycophenolate mofetil—systemic scleroderma	0.00023	0.00256	CcSEcCtD
Auranofin—Vomiting—Pentoxifylline—systemic scleroderma	0.000229	0.00255	CcSEcCtD
Auranofin—Rash—Pentoxifylline—systemic scleroderma	0.000227	0.00253	CcSEcCtD
Auranofin—Dermatitis—Pentoxifylline—systemic scleroderma	0.000227	0.00253	CcSEcCtD
Auranofin—IKBKB—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000226	0.00706	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Captopril—systemic scleroderma	0.000223	0.00249	CcSEcCtD
Auranofin—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.000223	0.00248	CcSEcCtD
Auranofin—IKBKB—TCR Signaling Pathway—IL1A—systemic scleroderma	0.000222	0.00693	CbGpPWpGaD
Auranofin—IKBKB—Interleukin-1 signaling—IL1B—systemic scleroderma	0.000221	0.00691	CbGpPWpGaD
Auranofin—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00022	0.00245	CcSEcCtD
Auranofin—Pruritus—Mometasone—systemic scleroderma	0.00022	0.00245	CcSEcCtD
Auranofin—Anaemia—Lisinopril—systemic scleroderma	0.000219	0.00244	CcSEcCtD
Auranofin—IKBKB—NOD pathway—IL1B—systemic scleroderma	0.000217	0.00677	CbGpPWpGaD
Auranofin—Angioedema—Lisinopril—systemic scleroderma	0.000217	0.00241	CcSEcCtD
Auranofin—Abdominal pain—Captopril—systemic scleroderma	0.000216	0.0024	CcSEcCtD
Auranofin—Anorexia—Leflunomide—systemic scleroderma	0.000215	0.00239	CcSEcCtD
Auranofin—Nausea—Pentoxifylline—systemic scleroderma	0.000214	0.00238	CcSEcCtD
Auranofin—Diarrhoea—Mometasone—systemic scleroderma	0.000213	0.00237	CcSEcCtD
Auranofin—Leukopenia—Lisinopril—systemic scleroderma	0.000212	0.00236	CcSEcCtD
Auranofin—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000211	0.00235	CcSEcCtD
Auranofin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00021	0.00234	CcSEcCtD
Auranofin—Dermatitis exfoliative—Methotrexate—systemic scleroderma	0.000207	0.0023	CcSEcCtD
Auranofin—Anorexia—Mycophenolic acid—systemic scleroderma	0.000205	0.00228	CcSEcCtD
Auranofin—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000205	0.00228	CcSEcCtD
Auranofin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000203	0.00226	CcSEcCtD
Auranofin—IKBKB—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000201	0.00626	CbGpPWpGaD
Auranofin—Dyspepsia—Leflunomide—systemic scleroderma	0.000198	0.0022	CcSEcCtD
Auranofin—Vomiting—Mometasone—systemic scleroderma	0.000198	0.0022	CcSEcCtD
Auranofin—Rash—Mometasone—systemic scleroderma	0.000196	0.00218	CcSEcCtD
Auranofin—Dermatitis—Mometasone—systemic scleroderma	0.000196	0.00218	CcSEcCtD
Auranofin—Decreased appetite—Leflunomide—systemic scleroderma	0.000196	0.00218	CcSEcCtD
Auranofin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000195	0.00217	CcSEcCtD
Auranofin—Pruritus—Captopril—systemic scleroderma	0.000193	0.00215	CcSEcCtD
Auranofin—Constipation—Leflunomide—systemic scleroderma	0.000192	0.00214	CcSEcCtD
Auranofin—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000192	0.00214	CcSEcCtD
Auranofin—IKBKB—Signaling by Interleukins—IL1A—systemic scleroderma	0.000192	0.00599	CbGpPWpGaD
Auranofin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00019	0.00211	CcSEcCtD
Auranofin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000189	0.00211	CcSEcCtD
Auranofin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000189	0.0021	CcSEcCtD
Auranofin—Neutropenia—Prednisone—systemic scleroderma	0.000189	0.0021	CcSEcCtD
Auranofin—Abdominal pain—Azathioprine—systemic scleroderma	0.000188	0.0021	CcSEcCtD
Auranofin—Diarrhoea—Captopril—systemic scleroderma	0.000187	0.00208	CcSEcCtD
Auranofin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000187	0.00208	CcSEcCtD
Auranofin—IKBKB—B Cell Activation—BLK—systemic scleroderma	0.000186	0.00582	CbGpPWpGaD
Auranofin—IKBKB—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000186	0.00581	CbGpPWpGaD
Auranofin—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000186	0.00207	CcSEcCtD
Auranofin—Nausea—Mometasone—systemic scleroderma	0.000185	0.00206	CcSEcCtD
Auranofin—Anorexia—Lisinopril—systemic scleroderma	0.000184	0.00205	CcSEcCtD
Auranofin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000184	0.00205	CcSEcCtD
Auranofin—Constipation—Mycophenolic acid—systemic scleroderma	0.000184	0.00204	CcSEcCtD
Auranofin—Weight decreased—Prednisone—systemic scleroderma	0.000183	0.00203	CcSEcCtD
Auranofin—Urticaria—Leflunomide—systemic scleroderma	0.000179	0.00199	CcSEcCtD
Auranofin—Abdominal pain—Leflunomide—systemic scleroderma	0.000178	0.00198	CcSEcCtD
Auranofin—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000177	0.00196	CcSEcCtD
Auranofin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000176	0.00195	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000174	0.00544	CbGpPWpGaD
Auranofin—Vomiting—Captopril—systemic scleroderma	0.000174	0.00193	CcSEcCtD
Auranofin—Rash—Captopril—systemic scleroderma	0.000172	0.00192	CcSEcCtD
Auranofin—Dermatitis—Captopril—systemic scleroderma	0.000172	0.00191	CcSEcCtD
Auranofin—IKBKB—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000171	0.00536	CbGpPWpGaD
Auranofin—Dyspepsia—Lisinopril—systemic scleroderma	0.00017	0.00189	CcSEcCtD
Auranofin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00017	0.00189	CcSEcCtD
Auranofin—Decreased appetite—Lisinopril—systemic scleroderma	0.000168	0.00187	CcSEcCtD
Auranofin—Eosinophilia—Methotrexate—systemic scleroderma	0.000167	0.00186	CcSEcCtD
Auranofin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000166	0.00185	CcSEcCtD
Auranofin—Constipation—Lisinopril—systemic scleroderma	0.000165	0.00184	CcSEcCtD
Auranofin—Diarrhoea—Azathioprine—systemic scleroderma	0.000163	0.00181	CcSEcCtD
Auranofin—Nausea—Captopril—systemic scleroderma	0.000162	0.00181	CcSEcCtD
Auranofin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000162	0.0018	CcSEcCtD
Auranofin—Pancytopenia—Methotrexate—systemic scleroderma	0.00016	0.00178	CcSEcCtD
Auranofin—IKBKB—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000159	0.00497	CbGpPWpGaD
Auranofin—Pruritus—Leflunomide—systemic scleroderma	0.000159	0.00177	CcSEcCtD
Auranofin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000158	0.00176	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000158	0.00493	CbGpPWpGaD
Auranofin—Neutropenia—Methotrexate—systemic scleroderma	0.000158	0.00176	CcSEcCtD
Auranofin—IKBKB—Leptin signaling pathway—NOS3—systemic scleroderma	0.000157	0.00491	CbGpPWpGaD
Auranofin—Diarrhoea—Leflunomide—systemic scleroderma	0.000154	0.00171	CcSEcCtD
Auranofin—Urticaria—Lisinopril—systemic scleroderma	0.000154	0.00171	CcSEcCtD
Auranofin—Abdominal pain—Lisinopril—systemic scleroderma	0.000153	0.0017	CcSEcCtD
Auranofin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000152	0.00169	CcSEcCtD
Auranofin—Vomiting—Azathioprine—systemic scleroderma	0.000152	0.00169	CcSEcCtD
Auranofin—Eye disorder—Prednisone—systemic scleroderma	0.000151	0.00168	CcSEcCtD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000151	0.00471	CbGpPWpGaD
Auranofin—Rash—Azathioprine—systemic scleroderma	0.00015	0.00167	CcSEcCtD
Auranofin—Dermatitis—Azathioprine—systemic scleroderma	0.00015	0.00167	CcSEcCtD
Auranofin—IKBKB—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.00015	0.00468	CbGpPWpGaD
Auranofin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000149	0.00166	CcSEcCtD
Auranofin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000147	0.00164	CcSEcCtD
Auranofin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000147	0.00163	CcSEcCtD
Auranofin—Stomatitis—Methotrexate—systemic scleroderma	0.000147	0.00163	CcSEcCtD
Auranofin—Conjunctivitis—Methotrexate—systemic scleroderma	0.000146	0.00163	CcSEcCtD
Auranofin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000145	0.00161	CcSEcCtD
Auranofin—Haematuria—Methotrexate—systemic scleroderma	0.000143	0.0016	CcSEcCtD
Auranofin—Vomiting—Leflunomide—systemic scleroderma	0.000143	0.00159	CcSEcCtD
Auranofin—Alopecia—Prednisone—systemic scleroderma	0.000143	0.00159	CcSEcCtD
Auranofin—Rash—Leflunomide—systemic scleroderma	0.000142	0.00158	CcSEcCtD
Auranofin—Dermatitis—Leflunomide—systemic scleroderma	0.000142	0.00158	CcSEcCtD
Auranofin—Nausea—Azathioprine—systemic scleroderma	0.000142	0.00158	CcSEcCtD
Auranofin—Agranulocytosis—Methotrexate—systemic scleroderma	0.00014	0.00156	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—MMP9—systemic scleroderma	0.00014	0.00436	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000139	0.00154	CcSEcCtD
Auranofin—Pruritus—Lisinopril—systemic scleroderma	0.000137	0.00152	CcSEcCtD
Auranofin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000137	0.00152	CcSEcCtD
Auranofin—Rash—Mycophenolic acid—systemic scleroderma	0.000135	0.00151	CcSEcCtD
Auranofin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000135	0.00151	CcSEcCtD
Auranofin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000135	0.0015	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000135	0.0042	CbGpPWpGaD
Auranofin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000134	0.00149	CcSEcCtD
Auranofin—IKBKB—Leptin signaling pathway—IL1B—systemic scleroderma	0.000134	0.00418	CbGpPWpGaD
Auranofin—Nausea—Leflunomide—systemic scleroderma	0.000134	0.00149	CcSEcCtD
Auranofin—IKBKB—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000133	0.00416	CbGpPWpGaD
Auranofin—Diarrhoea—Lisinopril—systemic scleroderma	0.000132	0.00147	CcSEcCtD
Auranofin—Visual impairment—Methotrexate—systemic scleroderma	0.00013	0.00145	CcSEcCtD
Auranofin—Anaemia—Prednisone—systemic scleroderma	0.00013	0.00145	CcSEcCtD
Auranofin—Angioedema—Prednisone—systemic scleroderma	0.000129	0.00143	CcSEcCtD
Auranofin—Nausea—Mycophenolic acid—systemic scleroderma	0.000128	0.00142	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	0.000127	0.00396	CbGpPWpGaD
Auranofin—Eye disorder—Methotrexate—systemic scleroderma	0.000126	0.00141	CcSEcCtD
Auranofin—Vomiting—Lisinopril—systemic scleroderma	0.000123	0.00137	CcSEcCtD
Auranofin—Rash—Lisinopril—systemic scleroderma	0.000122	0.00136	CcSEcCtD
Auranofin—Dermatitis—Lisinopril—systemic scleroderma	0.000122	0.00136	CcSEcCtD
Auranofin—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000121	0.00376	CbGpPWpGaD
Auranofin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00012	0.00133	CcSEcCtD
Auranofin—Alopecia—Methotrexate—systemic scleroderma	0.000119	0.00133	CcSEcCtD
Auranofin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000116	0.00129	CcSEcCtD
Auranofin—IKBKB—TCR Signaling Pathway—IL1B—systemic scleroderma	0.000116	0.00361	CbGpPWpGaD
Auranofin—Dysgeusia—Methotrexate—systemic scleroderma	0.000115	0.00128	CcSEcCtD
Auranofin—Nausea—Lisinopril—systemic scleroderma	0.000115	0.00128	CcSEcCtD
Auranofin—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000113	0.00351	CbGpPWpGaD
Auranofin—Anorexia—Prednisone—systemic scleroderma	0.000109	0.00122	CcSEcCtD
Auranofin—Anaemia—Methotrexate—systemic scleroderma	0.000109	0.00121	CcSEcCtD
Auranofin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000108	0.0012	CcSEcCtD
Auranofin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00119	CcSEcCtD
Auranofin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000107	0.00119	CcSEcCtD
Auranofin—Leukopenia—Methotrexate—systemic scleroderma	0.000105	0.00117	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	0.000105	0.00327	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—CCL2—systemic scleroderma	0.000103	0.00323	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000102	0.0032	CbGpPWpGaD
Auranofin—Dyspepsia—Prednisone—systemic scleroderma	0.000101	0.00113	CcSEcCtD
Auranofin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000101	0.00112	CcSEcCtD
Auranofin—IKBKB—Signaling by Interleukins—IL1B—systemic scleroderma	0.0001	0.00312	CbGpPWpGaD
Auranofin—Decreased appetite—Prednisone—systemic scleroderma	9.98e-05	0.00111	CcSEcCtD
Auranofin—Constipation—Prednisone—systemic scleroderma	9.82e-05	0.00109	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	9.63e-05	0.00301	CbGpPWpGaD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	9.5e-05	0.00297	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	9.42e-05	0.00294	CbGpPWpGaD
Auranofin—Thrombocytopenia—Methotrexate—systemic scleroderma	9.4e-05	0.00105	CcSEcCtD
Auranofin—Gastrointestinal pain—Prednisone—systemic scleroderma	9.39e-05	0.00105	CcSEcCtD
Auranofin—Anorexia—Methotrexate—systemic scleroderma	9.15e-05	0.00102	CcSEcCtD
Auranofin—Urticaria—Prednisone—systemic scleroderma	9.12e-05	0.00102	CcSEcCtD
Auranofin—Abdominal pain—Prednisone—systemic scleroderma	9.08e-05	0.00101	CcSEcCtD
Auranofin—IKBKB—TCR Signaling Pathway—TGFB1—systemic scleroderma	8.99e-05	0.00281	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	8.94e-05	0.00279	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CSK—systemic scleroderma	8.64e-05	0.0027	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—ITGAM—systemic scleroderma	8.46e-05	0.00264	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CD247—systemic scleroderma	8.46e-05	0.00264	CbGpPWpGaD
Auranofin—Dyspepsia—Methotrexate—systemic scleroderma	8.45e-05	0.00094	CcSEcCtD
Auranofin—Decreased appetite—Methotrexate—systemic scleroderma	8.34e-05	0.000929	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	8.21e-05	0.00256	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	8.17e-05	0.00255	CbGpPWpGaD
Auranofin—Pruritus—Prednisone—systemic scleroderma	8.13e-05	0.000904	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—CD247—systemic scleroderma	8.13e-05	0.00254	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—TNFAIP3—systemic scleroderma	7.92e-05	0.00247	CbGpPWpGaD
Auranofin—Diarrhoea—Prednisone—systemic scleroderma	7.86e-05	0.000875	CcSEcCtD
Auranofin—Gastrointestinal pain—Methotrexate—systemic scleroderma	7.85e-05	0.000874	CcSEcCtD
Auranofin—ALB—Folate Metabolism—IL1B—systemic scleroderma	7.83e-05	0.00245	CbGpPWpGaD
Auranofin—Urticaria—Methotrexate—systemic scleroderma	7.63e-05	0.000849	CcSEcCtD
Auranofin—Abdominal pain—Methotrexate—systemic scleroderma	7.59e-05	0.000844	CcSEcCtD
Auranofin—IKBKB—Adaptive Immune System—BLK—systemic scleroderma	7.52e-05	0.00235	CbGpPWpGaD
Auranofin—Vomiting—Prednisone—systemic scleroderma	7.3e-05	0.000813	CcSEcCtD
Auranofin—Rash—Prednisone—systemic scleroderma	7.24e-05	0.000806	CcSEcCtD
Auranofin—Dermatitis—Prednisone—systemic scleroderma	7.24e-05	0.000805	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—IL1B—systemic scleroderma	7.02e-05	0.00219	CbGpPWpGaD
Auranofin—Nausea—Prednisone—systemic scleroderma	6.82e-05	0.000759	CcSEcCtD
Auranofin—Pruritus—Methotrexate—systemic scleroderma	6.79e-05	0.000756	CcSEcCtD
Auranofin—Diarrhoea—Methotrexate—systemic scleroderma	6.57e-05	0.000731	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	6.22e-05	0.00194	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SELP—systemic scleroderma	6.21e-05	0.00194	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CTLA4—systemic scleroderma	6.16e-05	0.00192	CbGpPWpGaD
Auranofin—Vomiting—Methotrexate—systemic scleroderma	6.1e-05	0.000679	CcSEcCtD
Auranofin—Rash—Methotrexate—systemic scleroderma	6.05e-05	0.000674	CcSEcCtD
Auranofin—Dermatitis—Methotrexate—systemic scleroderma	6.05e-05	0.000673	CcSEcCtD
Auranofin—ALB—Hemostasis—RHOB—systemic scleroderma	5.8e-05	0.00181	CbGpPWpGaD
Auranofin—Nausea—Methotrexate—systemic scleroderma	5.7e-05	0.000635	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—TGFB1—systemic scleroderma	5.45e-05	0.0017	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CSK—systemic scleroderma	5.28e-05	0.00165	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CSK—systemic scleroderma	5.24e-05	0.00164	CbGpPWpGaD
Auranofin—ALB—Platelet degranulation—TGFB1—systemic scleroderma	5.22e-05	0.00163	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IRF5—systemic scleroderma	5.16e-05	0.00161	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—HLA-DQB1—systemic scleroderma	5.07e-05	0.00158	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.98e-05	0.00156	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	4.97e-05	0.00155	CbGpPWpGaD
Auranofin—ALB—Hemostasis—ITGAM—systemic scleroderma	4.97e-05	0.00155	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IRF8—systemic scleroderma	4.93e-05	0.00154	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD247—systemic scleroderma	4.93e-05	0.00154	CbGpPWpGaD
Auranofin—IKBKB—Immune System—ITGAM—systemic scleroderma	4.93e-05	0.00154	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SMAD7—systemic scleroderma	4.81e-05	0.0015	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD40LG—systemic scleroderma	4.79e-05	0.0015	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	4.66e-05	0.00146	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TNFAIP3—systemic scleroderma	4.61e-05	0.00144	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BLK—systemic scleroderma	4.56e-05	0.00142	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.77e-05	0.00118	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CTLA4—systemic scleroderma	3.74e-05	0.00117	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RHOB—systemic scleroderma	3.72e-05	0.00116	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HSPG2—systemic scleroderma	3.51e-05	0.0011	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CSK—systemic scleroderma	3.39e-05	0.00106	CbGpPWpGaD
Auranofin—IKBKB—Immune System—HLA-DQB1—systemic scleroderma	3.08e-05	0.00096	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1A—systemic scleroderma	2.92e-05	0.000912	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD40LG—systemic scleroderma	2.9e-05	0.000907	CbGpPWpGaD
Auranofin—ALB—Hemostasis—MMP1—systemic scleroderma	2.49e-05	0.000777	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	2.31e-05	0.000723	CbGpPWpGaD
Auranofin—ALB—Metabolism—HSPG2—systemic scleroderma	2.22e-05	0.000693	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EDN1—systemic scleroderma	1.9e-05	0.000593	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS3—systemic scleroderma	1.8e-05	0.000564	CbGpPWpGaD
Auranofin—ALB—Metabolism—CTGF—systemic scleroderma	1.68e-05	0.000525	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1B—systemic scleroderma	1.52e-05	0.000476	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CCL2—systemic scleroderma	1.3e-05	0.000406	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TGFB1—systemic scleroderma	1.19e-05	0.000373	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOS3—systemic scleroderma	1.16e-05	0.000361	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP9—systemic scleroderma	9.29e-06	0.00029	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TGFB1—systemic scleroderma	7.65e-06	0.000239	CbGpPWpGaD
Auranofin—ALB—Metabolism—NOS3—systemic scleroderma	7.32e-06	0.000228	CbGpPWpGaD
